Four years after being taken private, Parexel has been sold again, with Goldman Sachs' private equity arm and EQT paying $8.5 billion to claim ownership of the contract research organisatio
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
